Back to results
US 2023/0414705 A1Published application
Hard Tissue Therapeutics
AssigneeOrthotrophix, Inc.
InventorsYoshinari Kumagai, Dawn McGuire, Meghan Miller, David Rosen
Life of this patent
Estimating the term…
Abstract
Compounds, pharmaceutical compositions, and a method of treating hard tissue diseases and disorders are disclosed. The compounds may be a peptide and is structured to bind integrin αvβ3 expressed by osteocytes and by selective binding to the cell surface integrin on hard tissue forming cells regulate three-dimensional bone shape, cartilage formation and repair.
Claims20
-20. (canceled)
A method of determining efficacy of a peptide comprising:
- (a) testing and confirming that the peptide binds integrin αVβ3;
- (b) injecting a subject with the peptide confirmed in step (a) to potentially be efficacious and thereby determining if binding to integrin αVβ3 is at a level so as to result in improving joint function upon injection into a subject.
A method of determining efficacy of a peptide, comprising:
- (a) testing and confirming that a peptide binds integrin αVβ3 expressed by osteocytes;
- (b) testing and confirming that the peptide is agonistic on binding to integrin αVβ3 expressed by osteocytes, and is not antagonistic, inhibitory, or blocking;
- and
- (c) testing and confirming that binding to integrin αVβ3 expressed by osteocytes is at a level so as to result in improving joint function upon injection into a subject.
1 more element
Dependencies are inferred from the claim text.